2 ASX growth shares I reckon are buys right now

I think the share market sell-off earlier this year has opened up a number of opportunities.

| More on:
Two children hold on tightly to books hugged against their chests, as if they were holding on to ASX shares for the long term.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The current investment environment seems like a good time to go hunting for ASX growth shares
  • The Betashares Nasdaq 100 ETF is invested in many of the world’s leading technology companies like Apple and Microsoft
  • Gentrack is a business that provides software for utility businesses and airports

This year has been a fascinating and painful one for ASX growth shares. Strong inflation and higher interest rates have punished the valuations of many assets.

But, as Warren Buffett's famous advice goes, "be fearful when others are greedy, and greedy when others are fearful".

Investors have certainly become fearful during this year. ASX growth shares have taken a hit as long-term growth isn't worth as much today because of higher interest rates (due to discounted cash flow valuations).

Buffett once explained why interest rates matter so much:

"The value of every business, the value of a farm, the value of an apartment house, the value of any economic asset, is 100% sensitive to interest rates because all you are doing in investing is transferring some money to somebody now in exchange for what you expect the stream of money to be, to come in over a period of time, and the higher interest rates are, the less that present value is going to be. So every business, by its nature…its intrinsic valuation is 100% sensitive to interest rates."

I think the current environment has made the below two ASX growth share options attractive:

Betashares Nasdaq 100 ETF (ASX: NDQ)

This is an exchange-traded fund (ETF) that gives exposure to 100 of the largest non-financial companies listed on the NASDAQ. It comes with an annual management fee of 0.48%.

Plenty of the top holdings are probably recognisable to readers: Apple, Microsoft, Amazon.com, Alphabet, Tesla, Nvidia, PepsiCo, Meta Platforms, and Costco.

While a lot of the portfolio is invested in tech-related companies, there are other sectors represented in the holdings, including utilities, industrials, consumer staples, and so on.

I think names like Apple and Microsoft have resilient earnings – smartphones and Microsoft Office software seem very embedded in daily life.

I do feel higher interest rates have reduced the intrinsic value of many businesses, but some share prices have fallen significantly. It's not often we get the chance to buy, for example, Microsoft shares 28% lower than where they were at the start of a year.

The Betashares Nasdaq 100 ETF price has dropped 26% in price in 2022, so I'm thinking this ASX growth share is good value today for the long term.

Despite the decline, over the past three years it has delivered an average return per annum of 15.2% to 31 October 2022.

Gentrack Group Ltd (ASX: GTK)

The Gentrack share price is another that has taken a dive this year – it's down more than 25%.

Gentrack says it designs, builds and delivers "cloud-first revenue and customer experience solutions found at the heart of leading utilities and airports around the world".

Momentum seems to be returning to the business. It's yet to report its FY22 result for the year to 30 September 2022, but in February 2022 and May 2022, it advised that annual revenue was going to be $115 million (up from FY21 revenue of $105.7 million).

It had also said that FY22 earnings before interest, tax, depreciation and amortisation (EBITDA) was expected to be in the "low single digits" in terms of how many millions of dollars it expects to make.

But at the end of September, it said it's forecast to make revenue of $125 million and that EBITDA is expected to be in the mid-to-high single digits of millions of dollars.

The ASX growth share continues to win new customers as well as expand with existing clients.

It has also said that it's "well-positioned to capture the sizeable market opportunity created by the transformation of the utilities and airports across the world".

I think the opening up of borders can also have a useful impact on the airport software side of the business, as airports will have more earnings to spend.

Gentrack itself is growing its investment in research and development, as well as sales and marketing. This should help growth in the future.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Alphabet (A shares), Alphabet (C shares), Amazon, Apple, BETANASDAQ ETF UNITS, Costco Wholesale, Meta Platforms, Inc., Microsoft, Nvidia, and Tesla. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple. The Motley Fool Australia has positions in and has recommended BETANASDAQ ETF UNITS. The Motley Fool Australia has recommended Alphabet (A shares), Alphabet (C shares), Amazon, Apple, Meta Platforms, Inc., and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Happy shareholders clap and smile as they listen to a company earnings report.
Share Gainers

Why Artrya, Clinuvel, Imugene, and Pilbara Minerals shares are storming higher today

These shares are starting the week in a positive fashion. But why?

Read more »

Woman calculating dividends on calculator and working on a laptop.
Share Market News

Charter Hall Group declares interim distribution for 1H FY26

Charter Hall Group declares a 24.83-cent half-year distribution for the six months to 31 December 2025, with most of it…

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Andean Silver, Boss Energy, Chalice Mining, and Rio Tinto shares are falling today

These shares are starting the week in the red. But why?

Read more »

A man leaps from a stack of gold coins to the next, each one higher than the last.
Broker Notes

Up 300% this year, 3 reasons to buy this ASX All Ords gold stock today

A leading broker sees further ‘clear upside’ potential for this rocketing ASX gold stock.

Read more »

asx silver shares represented by silver bull statue next to silver bear statue
Share Fallers

Up 118% in 2025, why is this All Ords ASX silver share crashing on Monday?

Investors are punishing this outperforming ASX silver share today. But why?

Read more »

A couple sit in their home looking at a phone screen as if discussing a financial matter.
Share Market News

APA Group gains $1bn extra funding capacity after S&P credit rating change

S&P’s credit rating change gives APA Group over $1 billion in extra capacity to fund new energy infrastructure projects.

Read more »

two men in suits shake hands at the top of a shined wood boardroom table.
Share Market News

DigiCo Infrastructure REIT appoints new CEO and sets strategic growth path

DigiCo Infrastructure REIT has appointed Michael Juniper as CEO, with a focus on powering the next phase of digital infrastructure…

Read more »

Four smiling young medics with arms crossed stand outside a hospital.
Share Market News

Telix Pharmaceuticals updates investors as first patient is dosed in Phase 3 prostate cancer trial

Telix Pharmaceuticals updates on its prostate cancer Phase 3 trial, dosing the first Part 2 patient and outlining regulatory plans.

Read more »